Mark Eisner Sells 1,616 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Mark Eisner sold 1,616 shares of the firm’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $9.53, for a total transaction of $15,400.48. Following the completion of the transaction, the executive vice president directly owned 155,913 shares of the company’s stock, valued at approximately $1,485,850.89. The trade was a 1.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Mark Eisner also recently made the following trade(s):

• On Wednesday, February 25th, Mark Eisner sold 1,889 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.82, for a total value of $18,549.98.
• On Monday, February 23rd, Mark Eisner sold 2,089 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total value of $15,563.05.

Vir Biotechnology Stock Down 2.5%

Shares of NASDAQ VIR opened at $9.09 on Friday. The stock’s 50-day simple moving average is $7.01 and its two-hundred day simple moving average is $6.07. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $10.94. The firm has a market capitalization of $1.27 billion, a P/E ratio of -2.88 and a beta of 1.69.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The firm had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The company’s revenue for the quarter was up 417.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.76) EPS. As a group, research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Vir Biotechnology News Summary

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas agreed to a collaboration on Vir’s prostate‑cancer asset (VIR‑5500) that includes up‑front and potential milestone payments totaling up to ~$1.7B, materially de‑risking that program and improving commercialization prospects. Read More.
• Positive Sentiment: Q4 results surprised to the upside: EPS and roughly $64M revenue beat consensus, signaling stronger commercial traction and likely underpinning recent analyst optimism. Read More.
• Positive Sentiment: Analysts have raised targets and ratings following the results and deal flow (Needham moved its target to $18), supporting upside from fundamentals despite volatility. Read More.
• Neutral Sentiment: Management will present at TD Cowen and Leerink in early March — useful for additional color and Q&A but not an immediate earnings/cash catalyst. Read More.
• Neutral Sentiment: Increased media/peer comparisons (head‑to‑head coverage) have raised visibility and trading volume; this can amplify moves but doesn’t change Vir’s underlying cashflow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross), which strengthens the balance sheet but is dilutive and increased near‑term share supply — a clear short‑term negative for the stock. Read More.
• Negative Sentiment: Market coverage singled out the discounted offering as the proximate cause of the post‑rally pullback, triggering selling and higher volatility. Read More.
• Negative Sentiment: Multiple insider sales were disclosed last week (including CEO and other senior officers/directors), increasing visible supply and feeding negative sentiment alongside the offering. Individual filings and summaries are available in SEC/insider reports. Read More.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in Vir Biotechnology by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after purchasing an additional 1,390 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of Vir Biotechnology during the 3rd quarter worth approximately $38,000. Raymond James Financial Inc. purchased a new position in Vir Biotechnology during the second quarter valued at $35,000. UMB Bank n.a. boosted its stake in Vir Biotechnology by 1,418.7% during the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after acquiring an additional 6,597 shares in the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after purchasing an additional 4,899 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on VIR. Raymond James Financial upgraded shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective on the stock in a research report on Tuesday. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Needham & Company LLC increased their price objective on Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.89.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.